[ad_1]
Kim Yong-bum, Vice Chairman of the Financial Services Commission (KCCI), who deliberated on suspicion of misappropriation of Samsung Bio Logics, announced the details of his decision on December 12th, I said that I asked. The reason for the announcement of the "half-time" conclusion after the holding of five Supreme Court meetings is that it is difficult to say whether the results of the Council's audit surveillance alone are intentional or gross negligence.
○ Disclosure to refuse a modification to the FSS is only a conclusion
The same day, Samsung Bio Logics signed a joint venture agreement It was concluded that the fact that US Bioenergy was granted a subsidiary purchase option (claim for the stock
), but did not disclose it, constituted an obvious accounting violation. However, with respect to the accounting changes in the subsidiaries that suspect the accounting of the misdemeanors, it was necessary to suspend the judgment and to require supervision.
As a first step, the Financial Supervisory Service insisted that Samsung Bio Logics had "lost control" of its subsidiary Samsung Bio E Peace in 2015 and changed the accounting standard of a subsidiary into one. related company as "deliberate misappropriation". On this basis, he proposed to the Supreme Court to dismiss the director general, to charge the representative and the company to be prosecuted and to impose fines.
However, it is necessary to consider how Samsung Bio Logics should address in detail the details of the accounting for 2015.
However, after dismissing the application, the Supreme Court of Appeals declared that it was not appropriate to draw a conclusion. "We have discussed in detail the interpretation and facts of the related accounting standards, but we have decided that the details of the FSC's action against the underlying claims are insufficient in terms of clarity and specificity for the administrative provision. "
The FSS said: "We will do the same after the Supreme Court of Korea (KOSPI) has asked me to oversee the new presidency."
○ & # 39; Inevitable
Samsung Bio Logics immediately responded to the decision by stating: "We will seek legal remedies such as administrative disputes". According to Samsung Biologics, "According to IFRS, there is no need to disclose information." When disclosure was omitted, only major shareholders such as Samsung C & T, Samsung Electronics and Quintiles were missing. No investor has seen the damage, "he refuted.
Koo added:" While acknowledging the deliberate omission of today's announcement, I do not know what the damage is. " I did not disclose the grounds on which I deliberately judged it. Kim said, "It's hard to say at this point because the prosecution will file a complaint with the prosecutor to find out why he deliberately missed the disclosure." As for the merger of Samsung C & T and Cheil Industries, they did not respond "I can not make a clear decision."
There is also concern that this situation will continue for a long time before the release of the results of the new FSS audit.
The price of the Samsung Bio Logics action should be adjusted at the moment. "
Samsung Bio Logics 'stock price should be adjusted for the moment." In the securities market, Samsung Bio Logics' share price has risen by 3.42 % (4,000 won) compared to the previous day at 429,000 won, but after the announcement of the Addendum, the price limit dropped to 9.91%.
You have recommended
Copyright by dongA.com All Rights Reserved.
